DE102018107224A1 - Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten - Google Patents

Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten Download PDF

Info

Publication number
DE102018107224A1
DE102018107224A1 DE102018107224.4A DE102018107224A DE102018107224A1 DE 102018107224 A1 DE102018107224 A1 DE 102018107224A1 DE 102018107224 A DE102018107224 A DE 102018107224A DE 102018107224 A1 DE102018107224 A1 DE 102018107224A1
Authority
DE
Germany
Prior art keywords
cancer
peptide
cell
peptides
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102018107224.4A
Other languages
German (de)
English (en)
Inventor
Heiko Schuster
Franziska Hoffgaard
Jens FRITSCHE
Oliver Schoor
Toni Weinschenk
Chih-Chiang Tsou
Daniel Kowalewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to PE2020001251A priority Critical patent/PE20210376A1/es
Priority to JP2020536952A priority patent/JP7536642B2/ja
Priority to MA051890A priority patent/MA51890A/fr
Priority to EA202091754A priority patent/EA202091754A1/ru
Priority to PCT/EP2019/053168 priority patent/WO2019162110A1/en
Priority to SG10202010171VA priority patent/SG10202010171VA/en
Priority to BR122020014377A priority patent/BR122020014377A8/pt
Priority to MYPI2020005127A priority patent/MY200985A/en
Priority to CR20200365A priority patent/CR20200365A/es
Priority to CA3086916A priority patent/CA3086916A1/en
Priority to EP23216383.2A priority patent/EP4321529A3/en
Priority to KR1020207024053A priority patent/KR20200123134A/ko
Priority to MX2020007767A priority patent/MX2020007767A/es
Priority to EA202091833A priority patent/EA202091833A1/ru
Priority to KR1020207027250A priority patent/KR20200116527A/ko
Priority to EP19704315.1A priority patent/EP3755708A1/en
Priority to CN202411279163.8A priority patent/CN119306794A/zh
Priority to SG11202006630RA priority patent/SG11202006630RA/en
Priority to CN201980013690.5A priority patent/CN114040921A/zh
Priority to BR112020014272-7A priority patent/BR112020014272A2/pt
Priority to AU2019225879A priority patent/AU2019225879B2/en
Priority to PE2020001911A priority patent/PE20211300A1/es
Priority to CN202011611064.7A priority patent/CN112920257A/zh
Priority to US16/274,505 priority patent/US10993962B2/en
Priority to TW108105788A priority patent/TW201936630A/zh
Priority to TW111128553A priority patent/TWI837747B/zh
Priority to TW109118042A priority patent/TWI776160B/zh
Priority to US16/376,676 priority patent/US10894064B2/en
Priority to US16/376,727 priority patent/US11077142B2/en
Priority to US16/376,663 priority patent/US11033583B2/en
Publication of DE102018107224A1 publication Critical patent/DE102018107224A1/de
Priority to US16/659,256 priority patent/US10695373B2/en
Priority to US16/659,347 priority patent/US10695375B2/en
Priority to US16/659,291 priority patent/US10695374B2/en
Priority to US16/692,035 priority patent/US10695376B2/en
Priority to US16/692,108 priority patent/US10695377B2/en
Priority to US16/703,061 priority patent/US10709736B2/en
Priority to US16/703,034 priority patent/US10702553B2/en
Priority to US16/782,252 priority patent/US10709737B2/en
Priority to US16/782,620 priority patent/US10709738B2/en
Priority to US16/782,648 priority patent/US10772915B2/en
Priority to US16/790,062 priority patent/US10813953B2/en
Priority to US16/791,598 priority patent/US10751369B2/en
Priority to US16/791,591 priority patent/US10792307B2/en
Priority to US16/791,552 priority patent/US10799537B2/en
Priority to US16/814,508 priority patent/US10888582B2/en
Priority to US16/833,162 priority patent/US10888583B2/en
Priority to US16/833,110 priority patent/US10780122B2/en
Priority to US16/833,146 priority patent/US10780123B2/en
Priority to US16/833,175 priority patent/US10780124B2/en
Priority to US16/833,187 priority patent/US10792308B2/en
Priority to US16/864,929 priority patent/US10874695B2/en
Priority to US16/867,844 priority patent/US11013766B2/en
Priority to US16/867,823 priority patent/US10905719B2/en
Priority to US16/871,173 priority patent/US10869891B2/en
Priority to US16/871,156 priority patent/US10869890B2/en
Priority to US16/881,758 priority patent/US10869894B2/en
Priority to US16/881,547 priority patent/US10869892B2/en
Priority to US16/881,795 priority patent/US10874696B2/en
Priority to US16/881,572 priority patent/US10869893B2/en
Priority to US16/900,417 priority patent/US10888585B2/en
Priority to US16/900,430 priority patent/US10888586B2/en
Priority to US16/900,401 priority patent/US10888584B2/en
Priority to US16/900,360 priority patent/US10869896B2/en
Priority to US16/900,334 priority patent/US10869895B2/en
Priority to US16/914,073 priority patent/US11020433B2/en
Priority to US16/914,088 priority patent/US10898519B2/en
Priority to US16/914,059 priority patent/US10898518B2/en
Priority to US16/914,135 priority patent/US11033585B2/en
Priority to US16/917,211 priority patent/US10905720B2/en
Priority to US16/917,263 priority patent/US11020434B2/en
Priority to AU2020204568A priority patent/AU2020204568B2/en
Priority to MX2020007808A priority patent/MX2020007808A/es
Priority to CONC2020/0009869A priority patent/CO2020009869A2/es
Priority to CL2020002123A priority patent/CL2020002123A1/es
Priority to PH12020551295A priority patent/PH12020551295A1/en
Priority to IL276845A priority patent/IL276845A/en
Priority to IL276987A priority patent/IL276987A/en
Priority to CL2020002387A priority patent/CL2020002387A1/es
Priority to US17/089,279 priority patent/US10993964B2/en
Priority to US17/089,353 priority patent/US11013769B2/en
Priority to US17/089,502 priority patent/US11052113B2/en
Priority to US17/089,486 priority patent/US11026977B2/en
Priority to US17/089,330 priority patent/US11013768B2/en
Priority to US17/089,499 priority patent/US11040069B2/en
Priority to US17/097,692 priority patent/US11052114B2/en
Priority to US17/097,798 priority patent/US11065279B2/en
Priority to US17/117,611 priority patent/US11058727B2/en
Priority to US17/124,185 priority patent/US11103535B2/en
Priority to US17/150,257 priority patent/US11141437B2/en
Priority to US17/150,110 priority patent/US11154576B2/en
Priority to US17/155,933 priority patent/US11801264B2/en
Priority to US17/155,468 priority patent/US11147838B2/en
Priority to US17/155,960 priority patent/US11779606B2/en
Priority to US17/155,494 priority patent/US11147839B2/en
Priority to CL2021000841A priority patent/CL2021000841A1/es
Priority to CL2021000842A priority patent/CL2021000842A1/es
Priority to US17/229,411 priority patent/US11179418B2/en
Priority to US17/229,447 priority patent/US11197892B2/en
Priority to US17/366,894 priority patent/US11376281B2/en
Priority to US17/377,735 priority patent/US11951132B2/en
Priority to US17/377,724 priority patent/US11918607B2/en
Priority to US17/472,293 priority patent/US11369636B2/en
Priority to US17/478,036 priority patent/US11357797B2/en
Priority to JP2021199105A priority patent/JP7384884B2/ja
Priority to AU2022202520A priority patent/AU2022202520A1/en
Priority to AU2022202512A priority patent/AU2022202512B2/en
Priority to AU2022202522A priority patent/AU2022202522B2/en
Priority to US18/162,380 priority patent/US20230285460A1/en
Priority to US18/164,413 priority patent/US20230241109A1/en
Priority to US18/164,407 priority patent/US20230241108A1/en
Priority to US18/164,418 priority patent/US20230241110A1/en
Priority to US18/170,698 priority patent/US20230241113A1/en
Priority to US18/170,690 priority patent/US20230241112A1/en
Priority to US18/173,174 priority patent/US20230241114A1/en
Priority to US18/173,177 priority patent/US20230241115A1/en
Priority to US18/173,159 priority patent/US20230263830A1/en
Priority to US18/176,678 priority patent/US20230233612A1/en
Priority to US18/185,649 priority patent/US20230285461A1/en
Priority to US18/185,653 priority patent/US20230285462A1/en
Priority to JP2024063143A priority patent/JP7732024B2/ja
Priority to JP2024158604A priority patent/JP2025000689A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE102018107224.4A 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten Withdrawn DE102018107224A1 (de)

Priority Applications (121)

Application Number Priority Date Filing Date Title
PE2020001251A PE20210376A1 (es) 2018-02-21 2019-02-08 Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
JP2020536952A JP7536642B2 (ja) 2018-02-21 2019-02-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
MA051890A MA51890A (fr) 2018-02-21 2019-02-08 Peptides et combinaison de peptides d'origine non-canonique destinés à être utilisés en immunothérapie contre différents types de cancers
EA202091754A EA202091754A1 (ru) 2018-02-21 2019-02-08 Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака
PCT/EP2019/053168 WO2019162110A1 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
SG10202010171VA SG10202010171VA (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
BR122020014377A BR122020014377A8 (pt) 2018-02-21 2019-02-08 Peptídeo, anticorpo, receptor de célula t, aptâmero, ácido nucleico, célula hospedeira recombinante, método in vitro de produção de linfócitos t ativados, linfócito t ativado, composição farmacêutica, método de produção do peptídeo, uso de um número eficaz de células t ativadas, uso do peptídeo, kit e método in vitro de produção de uma vacina anticâncer personalizada
MYPI2020005127A MY200985A (en) 2018-02-21 2019-02-08 Peptides and Combination of Peptides Of Non-Canonical Origin for use in Immunotherapy Against Different Types Of Cancers
CR20200365A CR20200365A (es) 2018-02-21 2019-02-08 PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS DE ORIGEN NO CANÓNICO PARA EL USO EN LA INMUNOTERAPIA CONTRA DIFERENTES TIPOS DE CÁNCER (Divisional 2020-0360).
CA3086916A CA3086916A1 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
EP23216383.2A EP4321529A3 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
KR1020207024053A KR20200123134A (ko) 2018-02-21 2019-02-08 여러 유형의 암에 대한 면역요법에 사용하기 위한 펩티드, 및 비정규 기원의 펩티드의 조합
MX2020007767A MX2020007767A (es) 2018-02-21 2019-02-08 Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer.
EA202091833A EA202091833A1 (ru) 2018-02-21 2019-02-08 Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака
KR1020207027250A KR20200116527A (ko) 2018-02-21 2019-02-08 여러 유형의 암에 대한 면역요법에 사용하기 위한 펩티드, 및 비정규 기원의 펩티드의 조합
EP19704315.1A EP3755708A1 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
CN202411279163.8A CN119306794A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合
SG11202006630RA SG11202006630RA (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
CN201980013690.5A CN114040921A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合
BR112020014272-7A BR112020014272A2 (pt) 2018-02-21 2019-02-08 Peptídeo, anticorpo, receptor de células t, método in vitro para a produção de linfócitos t ativados, composição farmacêutica, método de produção, uso e kit
AU2019225879A AU2019225879B2 (en) 2018-02-21 2019-02-08 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
PE2020001911A PE20211300A1 (es) 2018-02-21 2019-02-08 Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
CN202011611064.7A CN112920257A (zh) 2018-02-21 2019-02-08 用于不同类型癌症免疫治疗的非经典来源的肽和肽组合
US16/274,505 US10993962B2 (en) 2018-02-21 2019-02-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
TW108105788A TW201936630A (zh) 2018-02-21 2019-02-21 用於不同類型癌症免疫治療的非經典來源的肽和肽組合
TW111128553A TWI837747B (zh) 2018-02-21 2019-02-21 用於不同類型癌症免疫治療的非經典來源的肽和肽組合
TW109118042A TWI776160B (zh) 2018-02-21 2019-02-21 用於不同類型癌症免疫治療的非經典來源的肽和肽組合
US16/376,676 US10894064B2 (en) 2018-02-21 2019-04-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/376,727 US11077142B2 (en) 2018-02-21 2019-04-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/376,663 US11033583B2 (en) 2018-02-21 2019-04-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/659,256 US10695373B2 (en) 2018-02-21 2019-10-21 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/659,347 US10695375B2 (en) 2018-02-21 2019-10-21 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/659,291 US10695374B2 (en) 2018-02-21 2019-10-21 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/692,035 US10695376B2 (en) 2018-02-21 2019-11-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/692,108 US10695377B2 (en) 2018-02-21 2019-11-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/703,061 US10709736B2 (en) 2018-02-21 2019-12-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/703,034 US10702553B2 (en) 2018-02-21 2019-12-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/782,252 US10709737B2 (en) 2018-02-21 2020-02-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/782,620 US10709738B2 (en) 2018-02-21 2020-02-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/782,648 US10772915B2 (en) 2018-02-21 2020-02-05 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/790,062 US10813953B2 (en) 2018-02-21 2020-02-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/791,598 US10751369B2 (en) 2018-02-21 2020-02-14 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/791,591 US10792307B2 (en) 2018-02-21 2020-02-14 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/791,552 US10799537B2 (en) 2018-02-21 2020-02-14 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/814,508 US10888582B2 (en) 2018-02-21 2020-03-10 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/833,162 US10888583B2 (en) 2018-02-21 2020-03-27 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/833,110 US10780122B2 (en) 2018-02-21 2020-03-27 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/833,146 US10780123B2 (en) 2018-02-21 2020-03-27 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/833,175 US10780124B2 (en) 2018-02-21 2020-03-27 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/833,187 US10792308B2 (en) 2018-02-21 2020-03-27 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/864,929 US10874695B2 (en) 2018-02-21 2020-05-01 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/867,844 US11013766B2 (en) 2018-02-21 2020-05-06 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/867,823 US10905719B2 (en) 2018-02-21 2020-05-06 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/871,173 US10869891B2 (en) 2018-02-21 2020-05-11 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/871,156 US10869890B2 (en) 2018-02-21 2020-05-11 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/881,758 US10869894B2 (en) 2018-02-21 2020-05-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/881,547 US10869892B2 (en) 2018-02-21 2020-05-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/881,795 US10874696B2 (en) 2018-02-21 2020-05-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/881,572 US10869893B2 (en) 2018-02-21 2020-05-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/900,417 US10888585B2 (en) 2018-02-21 2020-06-12 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/900,430 US10888586B2 (en) 2018-02-21 2020-06-12 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/900,401 US10888584B2 (en) 2018-02-21 2020-06-12 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/900,360 US10869896B2 (en) 2018-02-21 2020-06-12 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/900,334 US10869895B2 (en) 2018-02-21 2020-06-12 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/914,073 US11020433B2 (en) 2018-02-21 2020-06-26 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/914,088 US10898519B2 (en) 2018-02-21 2020-06-26 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/914,059 US10898518B2 (en) 2018-02-21 2020-06-26 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/914,135 US11033585B2 (en) 2018-02-21 2020-06-26 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/917,211 US10905720B2 (en) 2018-02-21 2020-06-30 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US16/917,263 US11020434B2 (en) 2018-02-21 2020-06-30 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
AU2020204568A AU2020204568B2 (en) 2018-02-21 2020-07-08 Peptides And Combination Of Peptides Of Non-Canonical Origin For Use In Immunotherapy Against Different Types Of Cancer
MX2020007808A MX2020007808A (es) 2018-02-21 2020-07-22 Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer.
CONC2020/0009869A CO2020009869A2 (es) 2018-02-21 2020-08-11 Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer
CL2020002123A CL2020002123A1 (es) 2018-02-21 2020-08-18 Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer.
PH12020551295A PH12020551295A1 (en) 2018-02-21 2020-08-20 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
IL276845A IL276845A (en) 2018-02-21 2020-08-20 Peptides and combinations of peptides of non-canonical origin for immunotherapy against various cancers
IL276987A IL276987A (en) 2018-02-21 2020-08-27 Peptides and combinations of peptides of non-canonical origin for immunotherapy against various cancers
CL2020002387A CL2020002387A1 (es) 2018-02-21 2020-09-15 Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123)
US17/089,279 US10993964B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/089,353 US11013769B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/089,502 US11052113B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/089,486 US11026977B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/089,330 US11013768B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/089,499 US11040069B2 (en) 2018-02-21 2020-11-04 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/097,692 US11052114B2 (en) 2018-02-21 2020-11-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/097,798 US11065279B2 (en) 2018-02-21 2020-11-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/117,611 US11058727B2 (en) 2018-02-21 2020-12-10 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/124,185 US11103535B2 (en) 2018-02-21 2020-12-16 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/150,257 US11141437B2 (en) 2018-02-21 2021-01-15 Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers
US17/150,110 US11154576B2 (en) 2018-02-21 2021-01-15 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/155,933 US11801264B2 (en) 2018-02-21 2021-01-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/155,468 US11147838B2 (en) 2018-02-21 2021-01-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/155,960 US11779606B2 (en) 2018-02-21 2021-01-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/155,494 US11147839B2 (en) 2018-02-21 2021-01-22 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
CL2021000841A CL2021000841A1 (es) 2018-02-21 2021-04-05 Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123)
CL2021000842A CL2021000842A1 (es) 2018-02-21 2021-04-05 Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123)
US17/229,411 US11179418B2 (en) 2018-02-21 2021-04-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/229,447 US11197892B2 (en) 2018-02-21 2021-04-13 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/366,894 US11376281B2 (en) 2018-02-21 2021-07-02 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/377,735 US11951132B2 (en) 2018-02-21 2021-07-16 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/377,724 US11918607B2 (en) 2018-02-21 2021-07-16 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/472,293 US11369636B2 (en) 2018-02-21 2021-09-10 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US17/478,036 US11357797B2 (en) 2018-02-21 2021-09-17 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
JP2021199105A JP7384884B2 (ja) 2018-02-21 2021-12-08 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
AU2022202520A AU2022202520A1 (en) 2018-02-21 2022-04-14 Peptides And Combination Of Peptides Of Non-Canonical Origin For Use In Immunotherapy Against Different Types Of Cancer
AU2022202512A AU2022202512B2 (en) 2018-02-21 2022-04-14 Peptides And Combination Of Peptides Of Non-Canonical Origin For Use In Immunotherapy Against Different Types Of Cancer
AU2022202522A AU2022202522B2 (en) 2018-02-21 2022-04-14 Peptides And Combination Of Peptides Of Non-Canonical Origin For Use In Immunotherapy Against Different Types Of Cancer
US18/162,380 US20230285460A1 (en) 2018-02-21 2023-01-31 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/164,413 US20230241109A1 (en) 2018-02-21 2023-02-03 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/164,407 US20230241108A1 (en) 2018-02-21 2023-02-03 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/164,418 US20230241110A1 (en) 2018-02-21 2023-02-03 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/170,698 US20230241113A1 (en) 2018-02-21 2023-02-17 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/170,690 US20230241112A1 (en) 2018-02-21 2023-02-17 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/173,174 US20230241114A1 (en) 2018-02-21 2023-02-23 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/173,177 US20230241115A1 (en) 2018-02-21 2023-02-23 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/173,159 US20230263830A1 (en) 2018-02-21 2023-02-23 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/176,678 US20230233612A1 (en) 2018-02-21 2023-03-01 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/185,649 US20230285461A1 (en) 2018-02-21 2023-03-17 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US18/185,653 US20230285462A1 (en) 2018-02-21 2023-03-17 Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
JP2024063143A JP7732024B2 (ja) 2018-02-21 2024-04-10 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2024158604A JP2025000689A (ja) 2018-02-21 2024-09-12 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862633325P 2018-02-21 2018-02-21
DE102018103944 2018-02-21
DE102018103944.1 2018-02-21
US62/633,325 2018-02-21

Publications (1)

Publication Number Publication Date
DE102018107224A1 true DE102018107224A1 (de) 2019-08-22

Family

ID=67482070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102018107224.4A Withdrawn DE102018107224A1 (de) 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Country Status (22)

Country Link
US (79) US10993962B2 (https=)
EP (2) EP4321529A3 (https=)
JP (4) JP7536642B2 (https=)
KR (2) KR20200123134A (https=)
CN (1) CN114040921A (https=)
AU (5) AU2019225879B2 (https=)
BR (2) BR112020014272A2 (https=)
CA (1) CA3086916A1 (https=)
CL (4) CL2020002123A1 (https=)
CO (1) CO2020009869A2 (https=)
CR (1) CR20200365A (https=)
DE (1) DE102018107224A1 (https=)
EA (2) EA202091754A1 (https=)
IL (2) IL276845A (https=)
MA (1) MA51890A (https=)
MX (2) MX2020007767A (https=)
MY (1) MY200985A (https=)
PE (2) PE20210376A1 (https=)
PH (1) PH12020551295A1 (https=)
SG (2) SG11202006630RA (https=)
TW (3) TWI776160B (https=)
WO (1) WO2019162110A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
WO2021041920A1 (en) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2022077464A1 (en) * 2020-10-16 2022-04-21 Apple Inc. System and method for fast beam tracking in a high frequency wireless communication system
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
AU2022348080A1 (en) * 2021-09-17 2024-05-02 Université de Montréal Novel tumor-specific antigens for colorectal cancer and uses thereof
CN119032273A (zh) 2022-01-25 2024-11-26 艾尔维缪恩公司 用于鉴定herv衍生的表位的新方法
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025211983A1 (ru) * 2024-04-05 2025-10-09 Общество с ограниченной ответственностью "Альбоген" Пептиды с противоопухолевой активностью

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1994029348A2 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Production of antibody fragments
WO1995018145A1 (en) 1993-12-24 1995-07-06 Ilexus Pty Ltd Conjugates of human mucin and a carbohydrate polymer and their use in cancer treatment
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2003068201A2 (en) 2002-02-13 2003-08-21 Technion Research & Development Foundation Ltd. High affinity antibody having a tcr-like specificity and use in detection and treatment
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
WO2004074322A1 (en) 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor
WO2004084798A2 (en) 2003-03-26 2004-10-07 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
EP1760088A1 (en) 2005-09-05 2007-03-07 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
DE102005041616A1 (de) * 2005-09-01 2007-03-08 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und deren Verwendungen
EP2113253A1 (en) 2008-04-30 2009-11-04 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
US20100113300A1 (en) 2002-11-09 2010-05-06 Immunocore Limited T cell receptor display
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
US20130096016A1 (en) 2010-04-16 2013-04-18 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US20130115191A1 (en) 2000-06-05 2013-05-09 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
WO2014191359A1 (en) 2013-05-28 2014-12-04 Rheinische Friedrich-Wilhelms Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
US20150125477A1 (en) * 2013-11-04 2015-05-07 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2017089780A2 (en) * 2015-11-23 2017-06-01 Immunocore Limited Peptides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5759812A (en) 1996-11-15 1998-06-02 Incyte Pharmaceuticals, Inc. Human selenium-binding protein
EP1109568A4 (en) 1998-09-04 2002-05-08 Ludwig Inst Cancer Res ANTIGENIC PEPTIDE ENCODED BY ANOTHER OPEN READING FRAMEWORK THAT STIMULATES THE PROLIFERATION OF MACROPHAGES
EP1001022A1 (en) 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, an alternative translation product of the tumour antigen LAGE-1
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
WO2014096399A1 (en) 2012-12-21 2014-06-26 Technische Universität Dresden Manipulation of hairy and split 3 (hes3) and its regulators/mediators as a new anti-cancer strategy
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
SG11201808629UA (en) 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
FR3070845B1 (fr) 2017-09-13 2021-07-30 Oreal Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1994029348A2 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Production of antibody fragments
WO1995018145A1 (en) 1993-12-24 1995-07-06 Ilexus Pty Ltd Conjugates of human mucin and a carbohydrate polymer and their use in cancer treatment
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20130115191A1 (en) 2000-06-05 2013-05-09 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
WO2003068201A2 (en) 2002-02-13 2003-08-21 Technion Research & Development Foundation Ltd. High affinity antibody having a tcr-like specificity and use in detection and treatment
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US20100113300A1 (en) 2002-11-09 2010-05-06 Immunocore Limited T cell receptor display
WO2004074322A1 (en) 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor
WO2004084798A2 (en) 2003-03-26 2004-10-07 Technion Research & Development Foundation Ltd. Antigen-presenting complex-binding compositions and uses thereof
DE102005041616A1 (de) * 2005-09-01 2007-03-08 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und deren Verwendungen
EP1760088A1 (en) 2005-09-05 2007-03-07 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
WO2007028574A2 (en) 2005-09-05 2007-03-15 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
EP2113253A1 (en) 2008-04-30 2009-11-04 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
US20130096016A1 (en) 2010-04-16 2013-04-18 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
WO2014191359A1 (en) 2013-05-28 2014-12-04 Rheinische Friedrich-Wilhelms Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
US20150125477A1 (en) * 2013-11-04 2015-05-07 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2017089780A2 (en) * 2015-11-23 2017-06-01 Immunocore Limited Peptides

Non-Patent Citations (204)

* Cited by examiner, † Cited by third party
Title
Accardi, L. et al., Int.J Cancer 134 (2014): 2742-2747
Aken, B. L. et al., Database.(Oxford) 2016 (2016)
Allison, J. P. et al., Science 270 (1995): 932-933
Ampie, L. et al., Front Oncol. 5 (2015): 12
Andersen, D. M. et al., Cell 160 (2015): 595-606
Andersen, R. S. et al., Nat.Protoc. 7 (2012): 891-902
Appay, V. et al., Eur.J Immunol. 36 (2006): 1805-1814
Armitage, J. O., Blood 110 (2007): 29-36
Aspden, J. L. et al., Elife. 3 (2014): e03528
Avigan, D. et al., Clin Cancer Res. 10 (2004): 4699-4708
Azevedo, R. et al., J Control Release 214 (2015): 40-61
Banchereau, J. et al., Cell 106 (2001): 271-274
Beatty, G. et al., J Immunol 166 (2001): 2276-2282
Beggs, J. D., Nature 275 (1978): 104-109
Benjamini, Y. et al., Journal of the Royal Statistical Society.Series B (Methodological), Vol.57 (1995): 289-300
Berman, R. S. et al., National Cancer Institute: PDQ(R) Colon Cancer Treatment (2015a)
Berman, R. S. et al., National Cancer Institute: PDQ(R) Rectal Cancer Treatment (2015b)
Boulter, J. M. et al., Protein Eng 16 (2003): 707-711
Braumuller, H. et al., Nature (2013)
Bray, F. et al., Int J Cancer 132 (2013): 1133-1145
Bridgewater, J. et al., J Hepatol. 60 (2014): 1268-1289
Brossart, P. et al., Blood 90 (1997): 1594-1599
Bruckdorfer, T. et al., Curr.Pharm.Biotechnol. 5 (2004): 29-43
Bujas, T. et al., Eur.J Histochem. 55 (2011)
Butterfield, L. H. et al., Clin Cancer Res 12 (2006): 2817-2825
Butterfield, L. H. et al., Clin Cancer Res 9 (2003): 5902-5908
Byrd, J. C. et al., N.Engl.J Med. 369 (2013): 32-42
Carballido, E. et al., Cancer Control 19 (2012): 54-67
Card, K. F. et al., Cancer Immunol Immunother. 53 (2004): 345-357
Chang, Y. S. et al., Cancer Chemother.Pharmacol. 59 (2007): 561-574
Chapiro, J. et al., Radiol.Med. 119 (2014): 476-482
Cohen, C. J. et al., J Immunol 170 (2003b): 4349-4361
Cohen, C. J. et al., J Mol Recognit. 16 (2003a): 324-332
Cohen, S. N. et al., Proc.Natl.Acad.Sci.U.S.A 69 (1972): 2110-2114
Coligan, J. E. et al., Current Protocols in Protein Science (1995)
Colombetti, S. et al., J Immunol. 176 (2006): 2730-2738
Coosemans, A. et al., Anticancer Res 33 (2013): 5495-5500
Counter, C. M. et al., Blood 85 (1995): 2315-2320
Dedes, K. J. et al., Sci.Transl.Med. 2 (2010): 53ra75
Dengjel, J. et al., Clin Cancer Res 12 (2006): 4163-4170
Denkberg, G. et al., J Immunol 171 (2003): 2197-2207
Economopoulou, P. et al., Ann.Transl.Med. 4 (2016): 173
Eichhorst, B. F. et al., Blood 107 (2006): 885-891
Emens, L. A., Expert.Rev.Anticancer Ther. 12 (2012): 1597-1611
Enguita-German, M. et al., World J Hepatol. 6 (2014): 716-737
Estey, E. H., Am.J Hematol. 89 (2014): 1063-1081
Falk, K. et al., Nature 351 (1991): 290-296
Ferlay et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], (2013)
Follenzi, A. et al., Nat Genet. 25 (2000): 217-222
Fong, L. et al., Proc.Natl.Acad.Sci.U.S.A 98 (2001): 8809-8814
Fuge, O. et al., Res Rep.Urol. 7 (2015): 65-79
Furman, R. R. et al., N.Engl.J Med. 370 (2014): 997-1007
Gabrilovich, D. I. et al., Nat Med. 2 (1996): 1096-1103
Gandhi, A. V. et al., Ann Surg.Oncol 20 Suppl 3 (2013): S636-S643
Gattinoni, L. et al., Nat Rev.Immunol 6 (2006): 383-393
Giannopoulos, K. et al., Int.J Oncol 29 (2006): 95-103
Giannopoulos, K. et al., Leukemia 24 (2010): 798-805
Gnjatic, S. et al., Proc Natl.Acad.Sci.U.S.A 100 (2003): 8862-8867
Godkin, A. et al., Int.Immunol 9 (1997): 905-911
Goede, V. et al., N.Engl.J Med. 370 (2014): 1101-1110
Gonzalez-Cao, M. et al., Cancer Biol Med 13 (2016): 483-488
Gragert, L. et al., Hum.Immunol. 74 (2013): 1313-1320
Granziero, L. et al., Blood 97 (2001): 2777-2783
Green, J. et al., Cochrane.Database.Syst.Rev (2005): CD002225
Green, M. R. et al., Molecular Cloning, A Laboratory Manual 4th (2012)
Greenfield, E. A., Antibodies: A Laboratory Manual 2nd (2014)
Grivas, P. D. et al., Semin.Cancer Biol 35 (2015): 125-132
Gunawardana, C. et al., Br.J Haematol. 142 (2008): 606-609
Gustafsson, C. et al., Trends Biotechnol. 22 (2004): 346-353
Hallek, Michael et al., ASH Annual Meeting Abstracts 112 (2008): 325
Harig, S. et al., Blood 98 (2001): 2999-3005
Hinrichs, C. S. et al., Nat.Biotechnol. 31 (2013): 999-1008
Holtl, L. et al., Clin.Cancer Res. 8 (2002): 3369-3376
Hörig, H. et al., Cancer Immunol Immunother. 49 (2000): 504-514
Hung, C. F. et al., Immunol.Rev 222 (2008): 43-69
Hus, I. et al., Oncol Rep. 20 (2008): 443-451
Hwang, M. L. et al., J Immunol. 179 (2007): 5829-5838
Inoue, H. et al., Int.J Cancer 63 (1995): 523-526
Jones, R. T. et al., Urol.Clin North Am. 43 (2016): 77-86
Jung, G. et al., Proc Natl Acad Sci U S A 84 (1987): 4611-4615
Kalos, M. et al., Sci.Transl.Med. 3 (2011): 95ra73
Kanthan, R. et al., J Oncol 2015 (2015): 967472
Kassiotis, G. et al., Philos.Trans.R Soc.Lond B Biol Sci. 372 (2017)
Kaufman, H. L. et al., Clin Cancer Res 14 (2008): 4843-4849
Khoury, G. A. et al., Sci.Rep. 1 (2011)
Kibbe, A. H., Handbook of Pharmaceutical Excipients rd (2000)
Kimura, H. et al., Int.J Oncol 30 (2007): 171-179
Klerk E. et al., Trends Genet. 31 (2015): 128-139
Knollman, H. et al., Ther.Adv.Urol. 7 (2015a): 312-330
Knollman, H. et al., Ther.Adv.Urol. 7 (2015b): 312-330
Koido, S. et al., World J Gastroenterol. 19 (2013): 8531-8542
Kono, K. et al., Cancer Sci. 100 (2009): 1502-1509
Krackhardt, A. M. et al., Blood 100 (2002): 2123-2131
Krieg, A. M., Nat Rev.Drug Discov. 5 (2006): 471-484
Krishnamurthy, J. et al., Clin Cancer Res 21 (2015): 3241-3251
Kronenberger, K. et al., J Immunother. 31 (2008): 723-730
Kuball, J. et al., Blood 109 (2007): 2331-2338
Laumont, C. M. et al., Cell Mol.Life Sci. 75 (2018): 607-621
Lee, W. C. et al., J Immunother. 28 (2005): 496-504
Li, Y. et al., Cancer Epidemiol. 39 (2015): 8-13
Liang, Z. et al., Zhonghua Zhong.Liu Za Zhi. 27 (2005): 534-537
Liddy, N. et al., Nat Med. 18 (2012): 980-987
Liepe, J. et al., Science 354 (2016): 354-358
Ljunggren, H. G. et al., J Exp.Med. 162 (1985): 1745-1759
Llovet, J. M. et al., N.Engl.J Med. 359 (2008): 378-390
Longenecker, B. M. et al., Ann N.Y.Acad.Sci. 690 (1993): 276-291
Lonsdale, J., Nat.Genet. 45 (2013): 580-585
Lukas, T. J. et al., Proc.Natl.Acad.Sci.U.S.A 78 (1981): 2791-2795
Lukka, H. et al., Clin Oncol (R Coll.Radiol.) 14 (2002): 203-212
Lundblad, R. L., Chemical Reagents for Protein Modification 3rd (2004)
Mantia-Smaldone, G. M. et al., Hum.Vaccin.Immunother. 8 (2012): 1179-1191
Marten, A. et al., Cancer Immunol.Immunother. 51 (2002): 637-644
Massari, F. et al., Cancer Treat.Rev. 41 (2015): 114-121
Matsueda, S. et al., World J Gastroenterol. 20 (2014): 1657-1666
Maus, M. V. et al., Blood 123 (2014): 2625-2635
Mayr, C. et al., Blood 105 (2005): 1566-1573
Mayr, C. et al., Exp.Hematol. 34 (2006): 44-53
Meziere, C. et al., J Immunol 159 (1997): 3230-3237
Miyagi, Y. et al., Clin Cancer Res 7 (2001): 3950-3962
Molina, J. R. et al., Mayo Clin Proc. 83 (2008): 584-594
Morgan, R. A. et al., Science 314 (2006): 126-129
Mortara, L. et al., Clin Cancer Res. 12 (2006): 3435-3443
Moulton, H. M. et al., Clin Cancer Res 8 (2002): 2044-2051
Mueller, L. N. et al., J Proteome.Res 7 (2008): 51-61
Mueller, L. N. et al., Proteomics. 7 (2007): 3470-3480
Muller, M. R. et al., Blood 103 (2004): 1763-1769
Mumberg, D. et al., Proc.Natl.Acad.Sci.U.S.A 96 (1999): 8633-8638
Nam, J. W. et al., Mol.Cells 39 (2016): 367-374
Nilsen, T. W. et al., Nature 463 (2010): 457-463
O'Brien, S. et al., Lancet Oncol 15 (2014): 48-58
Ohigashi, Y. et al., Clin Cancer Res. 11 (2005): 2947-2953
Okuno, K. et al., Exp.Ther Med. 2 (2011): 73-79
O'Leary, N. A. et al., Nucleic Acids Res 44 (2016): D733-D745
Olexiouk, V. et al., Nucleic Acids Res 44 (2016): D324-D329
Palma, M. et al., Cancer Immunol Immunother. 57 (2008): 1705-1710
Palmer, D. H. et al., Hepatology 49 (2009): 124-132
Palomba, M. L., Curr.Oncol Rep. 14 (2012): 433-440
Parikh, S. A. et al., Blood 118 (2011): 2062-2068
Phan, G. Q. et al., Cancer Control 20 (2013): 289-297
Pinheiro, J. et al., nlme: Linear and Nonlinear Mixed Effects Models (http://CRAN.R-project.org/packe=nlme) (2015)
Plebanski, M. et al., Eur.J Immunol 25 (1995): 1783-1787
Porta, C. et al., Virology 202 (1994): 949-955
Porter, D. L. et al., N.Engl.J Med. 365 (2011): 725-733
Quillien, V. et al., Anticancer Res. 17 (1997): 387-391
Quinn, D. I. et al., Urol.Oncol. (2015)
Rakic, M. et al., Hepatobiliary.Surg.Nutr. 3 (2014): 221-226
Rammensee, H. et al., Immunogenetics 50 (1999): 213-219
Reinisch, W. et al., J Immunother. 25 (2002): 489-499
Reinmuth, N. et al., Dtsch.Med.Wochenschr. 140 (2015): 329-333
Richards, S. et al., J Natl.Cancer Inst. 91 (1999): 861-868
Rini, B. I. et al., Cancer 107 (2006): 67-74
Rini, B. I. et al., Curr.Opin.Oncol. 20 (2008): 300-306
Robak, T. et al., Expert.Opin.Biol.Ther 14 (2014): 651-661
Rock, K. L. et al., Science 249 (1990): 918-921
Rouanne, M. et al., Crit Rev Oncol Hematol. 98 (2016): 106-115
Rucki, A. A. et al., World J Gastroenterol. 20 (2014): 2237-2246
Rundstedt, F. C. et al., Transl.Androl Urol. 4 (2015): 244-253
Saiki, R. K. et al., Science 239 (1988): 487-491
Salman, B. et al., Oncoimmunology. 2 (2013): e26662
Sangro, B. et al., J Clin Oncol 22 (2004): 1389-1397
Schetelig, J. et al., J Clin Oncol 26 (2008): 5094-5100
Schiavetti, F. et al., Cancer Res 62 (2002): 5510-5516
Schmidt, S. M. et al., Cancer Res 64 (2004): 1164-1170
Schmitt, T. M. et al., Hum.Gene Ther. 20 (2009): 1240-1248
Schölten, K. B. et al., Clin Immunol. 119 (2006): 135-145
Seeger, F. H. et al., Immunogenetics 49 (1999): 571-576
Sherman, F. et al., Laboratory Course Manual for Methods in Yeast Genetics (1986)
Shi, M. et al., World J Gastroenterol. 10 (2004): 1146-1151
Showel, M. M. et al., F1000Prime.Rep. 6 (2014): 96
Siegel, S. et al., Blood 102 (2003): 4416-4423
Singh-Jasuja, H. et al., Cancer Immunol.Immunother. 53 (2004): 187-195
Small, E. J. et al., J Clin Oncol. 24 (2006): 3089-3094
Spaner, D. E. et al., Cancer Immunol Immunother. 54 (2005): 635-646
Srivastava, N. et al., Cancer Manag.Res. 6 (2014): 279-289
Stahl, M. et al., Ann.Oncol. 24 Suppl 6 (2013): vi51-vi56
Steinberg, R. L. et al., Urol.Oncol (2016a)
Steinberg, R. L. et al., Urol.Oncol (2016b)
Stevanovic, S. et al., J Clin Oncol 33 (2015): 1543-1550
Stintzing, S., F1000Prime.Rep. 6 (2014): 108
Sturm, M. et al., BMC.Bioinformatics. 9 (2008): 163
Su, Z. et al., Cancer Res. 63 (2003): 2127-2133
Subramanian, R. P. et al., Retrovirology. 8 (2011): 90
Takayama, T. et al., Cancer 68 (1991): 2391-2396
Takayama, T. et al., Lancet 356 (2000): 802-807
Tanaka, F. et al., Int.J Oncol 10 (1997): 1113-1117
Teufel, R. et al., Cell Mol Life Sci. 62 (2005): 1755-1762
Thakkar, J. P. et al., Cancer Epidemiol.Biomarkers Prev. 23 (2014): 1985-1996
Toh, U. et al., Clin Cancer Res. 6 (2000): 4663-4673
Toh, U. et al., Int.J Clin Oncol 7 (2002): 372-375
Toomey, P. G. et al., Cancer Control 20 (2013): 32-42
Tran, E. et al., Science 344 (2014): 641-645
Vanderperre, B. et al., PLoS.One. 8 (2013): e70698
Vici, P. et al., J Exp.Clin Cancer Res 33 (2014): 29
Von Hoff, D. D. et al., N.Engl.J Med. 369 (2013): 1691-1703
Walter, S. et al., J Immunol 171 (2003): 4974-4978
Walter, S. et al., Nat Med. 18 (2012): 1254-1261
Wang, N. et al., Arch.Gynecol.Obstet. 283 (2011): 103-108
Wierda, W. G. et al., Blood 118 (2011): 5126-5129
Wilhelm, S. M. et al., Cancer Res 64 (2004): 7099-7109
Willcox, B. E. et al., Protein Sci. 8 (1999): 2418-2423
Wilson, P. M. et al., Nat Rev.Clin Oncol 11 (2014): 282-298
Wittig, B. et al., Hum.Gene Ther. 12 (2001): 267-278
Zaremba, S. et al., Cancer Res. 57 (1997): 4570-4577
Zufferey, R. et al., J Virol. 73 (1999): 2886-2892

Also Published As

Publication number Publication date
US20200038447A1 (en) 2020-02-06
US10695373B2 (en) 2020-06-30
AU2022202522A1 (en) 2022-05-12
CA3086916A1 (en) 2019-08-29
US20200268800A1 (en) 2020-08-27
JP7732024B2 (ja) 2025-09-01
US11147839B2 (en) 2021-10-19
US20210052653A1 (en) 2021-02-25
US20230241110A1 (en) 2023-08-03
US20230233612A1 (en) 2023-07-27
US11779606B2 (en) 2023-10-10
US20200323906A1 (en) 2020-10-15
US11951132B2 (en) 2024-04-09
US20200197441A1 (en) 2020-06-25
MA51890A (fr) 2020-12-30
US20230285462A1 (en) 2023-09-14
US20200085874A1 (en) 2020-03-19
EP4321529A3 (en) 2024-07-17
US20200093862A1 (en) 2020-03-26
TW201936630A (zh) 2019-09-16
US20200323918A1 (en) 2020-10-15
US20210330708A1 (en) 2021-10-28
US20230241108A1 (en) 2023-08-03
US10874696B2 (en) 2020-12-29
US10709737B2 (en) 2020-07-14
US20200206268A1 (en) 2020-07-02
US11052113B2 (en) 2021-07-06
JP2022050398A (ja) 2022-03-30
US10869893B2 (en) 2020-12-22
US20200261504A1 (en) 2020-08-20
US20210213064A1 (en) 2021-07-15
JP2024099580A (ja) 2024-07-25
US20200171091A1 (en) 2020-06-04
US20190255110A1 (en) 2019-08-22
US10869895B2 (en) 2020-12-22
US20230241112A1 (en) 2023-08-03
TWI837747B (zh) 2024-04-01
CL2020002123A1 (es) 2020-10-16
PE20210376A1 (es) 2021-03-02
JP7536642B2 (ja) 2024-08-20
US11369636B2 (en) 2022-06-28
CL2021000841A1 (es) 2021-09-03
US11376281B2 (en) 2022-07-05
KR20200123134A (ko) 2020-10-28
US10869896B2 (en) 2020-12-22
IL276987A (en) 2020-10-29
AU2019225879B2 (en) 2022-01-27
US20210052652A1 (en) 2021-02-25
CO2020009869A2 (es) 2020-08-21
US10772915B2 (en) 2020-09-15
US20200179453A1 (en) 2020-06-11
US10874695B2 (en) 2020-12-29
US20200323911A1 (en) 2020-10-15
US20200297770A1 (en) 2020-09-24
US20200323915A1 (en) 2020-10-15
US20200323910A1 (en) 2020-10-15
US11103535B2 (en) 2021-08-31
US20210145887A1 (en) 2021-05-20
US20200323909A1 (en) 2020-10-15
AU2022202520A1 (en) 2022-05-12
US10780122B2 (en) 2020-09-22
US10869894B2 (en) 2020-12-22
US20200155605A1 (en) 2020-05-21
US20230263830A1 (en) 2023-08-24
US11013768B2 (en) 2021-05-25
US20210137985A1 (en) 2021-05-13
US20200179454A1 (en) 2020-06-11
CR20200365A (es) 2020-09-18
US10780123B2 (en) 2020-09-22
CN114040921A (zh) 2022-02-11
US11154576B2 (en) 2021-10-26
US20210137986A1 (en) 2021-05-13
AU2022202522B2 (en) 2023-12-21
US11357797B2 (en) 2022-06-14
US20200163996A1 (en) 2020-05-28
US10894064B2 (en) 2021-01-19
US11918607B2 (en) 2024-03-05
US10792307B2 (en) 2020-10-06
US11033583B2 (en) 2021-06-15
US10993964B2 (en) 2021-05-04
US20190255113A1 (en) 2019-08-22
US11013769B2 (en) 2021-05-25
US20210052651A1 (en) 2021-02-25
EA202091754A1 (ru) 2021-02-08
US11179418B2 (en) 2021-11-23
US10905719B2 (en) 2021-02-02
EA202091833A1 (ru) 2020-11-25
US10751369B2 (en) 2020-08-25
US11077142B2 (en) 2021-08-03
US10869892B2 (en) 2020-12-22
US20210145886A1 (en) 2021-05-20
TW202043257A (zh) 2020-12-01
US20200108097A1 (en) 2020-04-09
US20200323919A1 (en) 2020-10-15
US10888582B2 (en) 2021-01-12
CL2020002387A1 (es) 2021-02-12
US20210069251A1 (en) 2021-03-11
US20210113619A1 (en) 2021-04-22
SG11202006630RA (en) 2020-09-29
JP2025000689A (ja) 2025-01-07
US20200297771A1 (en) 2020-09-24
MY200985A (en) 2024-01-27
US20200222465A1 (en) 2020-07-16
AU2022202512B2 (en) 2023-12-14
AU2022202512A1 (en) 2022-05-12
US20210052654A1 (en) 2021-02-25
US10869891B2 (en) 2020-12-22
US11020434B2 (en) 2021-06-01
MX2020007767A (es) 2020-10-12
US20230241115A1 (en) 2023-08-03
US11040069B2 (en) 2021-06-22
SG10202010171VA (en) 2020-11-27
US11065279B2 (en) 2021-07-20
US20200306305A1 (en) 2020-10-01
US10888583B2 (en) 2021-01-12
US10888585B2 (en) 2021-01-12
US20200360433A1 (en) 2020-11-19
US20230241113A1 (en) 2023-08-03
JP7384884B2 (ja) 2023-11-21
US10898518B2 (en) 2021-01-26
US10905720B2 (en) 2021-02-02
EP3755708A1 (en) 2020-12-30
US20200297772A1 (en) 2020-09-24
US20230285460A1 (en) 2023-09-14
US20210060077A1 (en) 2021-03-04
US20200155604A1 (en) 2020-05-21
EP4321529A2 (en) 2024-02-14
US10780124B2 (en) 2020-09-22
AU2020204568B2 (en) 2022-02-03
PH12020551295A1 (en) 2021-07-12
MX2020007808A (es) 2020-10-05
US10695375B2 (en) 2020-06-30
US11801264B2 (en) 2023-10-31
US20210145888A1 (en) 2021-05-20
US20200268798A1 (en) 2020-08-27
BR122020014377A8 (pt) 2023-03-28
US11147838B2 (en) 2021-10-19
TWI776160B (zh) 2022-09-01
US20220000922A1 (en) 2022-01-06
US20200038448A1 (en) 2020-02-06
US10888584B2 (en) 2021-01-12
US20200323914A1 (en) 2020-10-15
IL276845A (en) 2020-10-29
US11052114B2 (en) 2021-07-06
AU2019225879A1 (en) 2020-07-09
US20200306311A1 (en) 2020-10-01
US10888586B2 (en) 2021-01-12
US10709736B2 (en) 2020-07-14
US11020433B2 (en) 2021-06-01
US20210060074A1 (en) 2021-03-04
US20230241114A1 (en) 2023-08-03
US10695377B2 (en) 2020-06-30
US20210244765A1 (en) 2021-08-12
US20200323913A1 (en) 2020-10-15
US20200038446A1 (en) 2020-02-06
US20200085873A1 (en) 2020-03-19
US10709738B2 (en) 2020-07-14
US10898519B2 (en) 2021-01-26
US20200268799A1 (en) 2020-08-27
KR20200116527A (ko) 2020-10-12
US20210401892A1 (en) 2021-12-30
WO2019162110A1 (en) 2019-08-29
US20230241109A1 (en) 2023-08-03
US20210338735A1 (en) 2021-11-04
US10792308B2 (en) 2020-10-06
US11026977B2 (en) 2021-06-08
US20200306308A1 (en) 2020-10-01
TW202246307A (zh) 2022-12-01
US11141437B2 (en) 2021-10-12
US20210060078A1 (en) 2021-03-04
US11033585B2 (en) 2021-06-15
US20190255112A1 (en) 2019-08-22
CL2021000842A1 (es) 2021-09-03
US10799537B2 (en) 2020-10-13
US10993962B2 (en) 2021-05-04
US11013766B2 (en) 2021-05-25
PE20211300A1 (es) 2021-07-20
US20200323907A1 (en) 2020-10-15
US10702553B2 (en) 2020-07-07
US20210100845A1 (en) 2021-04-08
US20200261506A1 (en) 2020-08-20
US20210338734A1 (en) 2021-11-04
AU2020204568A1 (en) 2020-07-30
US20200261505A1 (en) 2020-08-20
US11058727B2 (en) 2021-07-13
BR112020014272A2 (pt) 2020-12-15
US10695374B2 (en) 2020-06-30
BR122020014377A2 (pt) 2020-12-29
US20190255164A1 (en) 2019-08-22
US10869890B2 (en) 2020-12-22
JP2021514178A (ja) 2021-06-10
US20210260120A1 (en) 2021-08-26
US11197892B2 (en) 2021-12-14
US10813953B2 (en) 2020-10-27
US20230285461A1 (en) 2023-09-14
US10695376B2 (en) 2020-06-30
US20200323916A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
DE102018107224A1 (de) Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US10314896B2 (en) Peptides and combination of peptides for use in immunotherapy against various cancers
TWI699377B (zh) 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
CN109734777B (zh) 用于各种癌症免疫治疗的新型肽、肽组合物和支架
TW201841934A (zh) 用於治療癌症免疫治療的新穎肽及其肽組合物
AU2022204032B2 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
US10383896B2 (en) Peptides and combination of peptides for use in immunotherapy against various cancers
DE102018115865A1 (de) A*03-restringierte Peptide zur Verwendung in der Immuntherapie gegen Krebs und verwandte Verfahren

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication
R082 Change of representative

Representative=s name: MICHALSKI HUETTERMANN & PARTNER PATENTANWAELTE, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee